There is
a need to advocate the value of genomics, biotech and medical
technologies as these new modalities enter and impact the healthcare
system and thereby improving patient outcomes, improving quality and
bringing value to the market place. Members of the Institute include
medical directors from purchasers, plans and provider systems.
